

EDITORIAL

Open Access



# Gazelles, unicorns, and dragons battle cancer through the Nanotechnology Startup Challenge

Rosemarie Truman\* and Cody J. Locke

\*Correspondence: [rt@thecenterforadvancinginnovation.org](mailto:rt@thecenterforadvancinginnovation.org)  
The Center for Advancing Innovation, INC., Bethesda, MD, USA

## Abstract

On March 4th, 2016, Springer's *Cancer Nanotechnology* office promoted the launch of the *Nanotechnology Startup Challenge in Cancer (NSC<sup>2</sup>)*. This innovation-development model is a partnership among our company, the Center for Advancing Innovation (CAI), MedImmune, the global biologics arm of AstraZeneca, and multiple institutes at the National Institutes of Health (NIH). *NSC<sup>2</sup>* "crowdsources" talent from around the world to launch startups with near-term, commercially viable cancer nanotechnology inventions, which were developed by the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Biomedical Imaging and Bioengineering (NIBIB). Crowdsourcing is a process in which one uses the internet to engage a large group of people in an activity, such as *NSC<sup>2</sup>*. For this initiative, CAI engaged universities, industry professionals, foundations, investors, relevant media outlets, seasoned entrepreneurs, and life sciences membership organizations to request that they participate in the challenge. From this outreach, fifty-six key thought leaders have enrolled in *NSC<sup>2</sup>* as judges, mentors, and/or advisors to challenge teams (<http://www.nscsquared.org/judges.html>). Along with crowdsourcing talent to bolt startups around NIH inventions, *NSC<sup>2</sup>* will also catalyze the launch of companies around "third-party" cancer nanotechnology inventions, which were conceived and developed outside of the NIH. Twenty-eight robust teams were accepted to the challenge on March 14th, 2016.

In total, 274 participants are competing in *NSC<sup>2</sup>*. These participants include life sciences industry players, serial entrepreneurs, angel investors, broadly trained scientists and engineers, experienced attorneys, and budding entrepreneurs with complementary backgrounds. Teams applied to the challenge through a Letter of Intent where they answered questions about their experience, role on the team and why they want to enter the challenge (Fig. 1). CAI evaluated these teams on more than forty criteria, which we developed through an analysis of successful startups. Each team has at least two currently enrolled students and one seasoned entrepreneur with more than 3 years in a startup. Twenty teams are based in the United States, three are based in China, two are based in Canada, two are based in England, and one is based in Brazil. Of the US teams, nine are based in the Maryland-Washington, DC-Virginia area.



homework and hands-on experiential learning exercises that focus on how to develop business plans, create financial models, perform live pitches and raise money.

To create near-mythical startups, *NSC*<sup>2</sup> teams will pursue a diversity of cancer nanotechnology inventions. The three exclusively therapeutic NIH inventions are photoactivatable liposomes for targeted drug delivery (Yavlovich et al. 2009, 2011; Puri et al. 2011), nucleic acid nanocubes for triggering RNA interference (Afonin et al. 2010, 2014a), and carbohydrate-encapsulated gold nanoparticles for inhibiting metastasis (Svarovsky and Barchi 2003; Brinās et al. 2012). Seven, one and two teams will pursue these therapeutics, respectively. The three exclusively diagnostic NIH inventions are a carbon nanotube transistor-based microarray binding sensor (Subramanian et al. 2012), a DNA-tethered bead immunoassay (Silver et al. 2015), and an enzyme-catalyzed gold nanoparticle-based colorimetric assay (Liu et al. 2014). Six, one, and two teams will pursue these diagnostics, respectively. The remaining inventions are nucleic acid nanoparticles (Afonin et al. 2014b), which have been shown to induce RNA interference (Afonin et al. 2015), and polymer-coated gold nanorod assemblies for targeted, imaging-guided photothermal therapy (Rong et al. 2015; Song et al. 2015). Two and three teams will pursue these multifunctional inventions, respectively. One may find overviews of these eight inventions, offered through *NSC*<sup>2</sup>, at <http://www.nscsquared.org/inventions.html>.

We interviewed an *NSC*<sup>2</sup> team leader, Elizabeth Cho-Fertikh, Ph.D. of Washington, DC, about her participation in this challenge. She noted, “I entered the challenge having been on the research and investor sides for many years, but never as an entrepreneur. The greatest value I have obtained so far from *NSC*<sup>2</sup> is developing a venture with so much support in a structured and well-organized manner from the sponsors, obtaining pearls of wisdom throughout the process.” Dr. Cho-Fertikh’s team will attempt to commercialize a third-party peptide-based approach to target alternatively activated M2 macrophages (Cieslewicz et al. 2013; Ngambenjawong et al. 2016).

Phase 1 of *NSC*<sup>2</sup> ended on April 17th, 2016. Each team submitted a two-minute “elevator speech”, which summarizes their chosen invention and potential startup, for public access and voting. Public voting was held between April 18th and April 22nd. The elevator speeches can be viewed at [https://www.youtube.com/playlist?list=PLvu6n-GsGFsYNp-TFHeYOrB\\_bpaYYrjHM](https://www.youtube.com/playlist?list=PLvu6n-GsGFsYNp-TFHeYOrB_bpaYYrjHM). Although public voting has closed, we would appreciate additional comments, likes, and shares of these elevator speeches. Feedback from the readers of *Cancer Nanotechnology* will be valuable to *NSC*<sup>2</sup> participants and would serve to further the educational goals of this NIH-supported initiative. CAI announced finalists from Phase 1 on April 25th. After moving on to Phase 2, teams will write ten-page business plans, create robust financial models, and pitch to our panel of judges. The *NSC*<sup>2</sup> teams may continue to add teammates through the challenge. To join an existing team, visit <http://www.nscsquared.org/find-a-team-member.html>.

You can find out more about each of the inventions from the references list below. We are most grateful to the *Cancer Nanotechnology* editorial team for helping to promote *NSC*<sup>2</sup>. Stay tuned for a Special Collection of articles, related to the inventions in *NSC*<sup>2</sup> and authored by the teams.

### Authors' contributions

RT and CJL created this article. RT and the National Institutes of Health conceived of this startup challenge accelerator model. CAI is executing the challenge. RT generated the graphical representation in Fig. 1. Both authors read and approved the final manuscript.

### Competing interests

The authors declare that they have no competing interests.

Received: 27 April 2016 Accepted: 12 May 2016

Published online: 09 June 2016

### References

- Afonin KA, Bindewald E, Yaghoobian AJ, Voss N, Jacovetty E, Shapiro BA, Jaeger L. In vitro assembly of cubic RNA-based scaffolds designed in silico. *Nat Nanotechnol*. 2010;5(9):676–82.
- Afonin KA, Kasprzak W, Bindewald E, Puppala PS, Diehl AR, Hall KT, Kim TJ, Zimmermann MT, Jernigan RL, Jaeger L, Shapiro BA. Computational and experimental characterization of RNA cubic nanoscaffolds. *Methods*. 2014a;67(2):256–65.
- Afonin KA, Viard M, Kagiampakis I, Case CL, Dobrovolskaia MA, Hofmann J, Vrzak A, Kireeva M, Kasprzak WK, KewalRamani VN, Shapiro BA. Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. *ACS Nano*. 2015;9(1):251–9.
- Afonin KA, Viard M, Koyfman AY, Martins AN, Kasprzak WK, Panigaj M, Desai R, Santhanam A, Grabow WW, Jaeger L, Heldman E, Reiser J, Chiu W, Freed EO, Shapiro BA. Multifunctional RNA nanoparticles. *Nano Lett*. 2014b;14(10):5662–71.
- Brinās RP, Sundgren A, Sahoo P, Morey S, Rittenhouse-Olson K, Wilding GE, Deng W, Barchi JJ Jr. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines. *Bioconjug Chem*. 2012;23(8):1513–23.
- Cieslewicz M, Tang J, Yu JL, Cao H, Zavaljevski M, Motoyama K, Lieber A, Raines EW, Pun SH. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. *Proc Natl Acad Sci USA*. 2013;110(40):15919–24.
- Liu D, Yang J, Wang HF, Wang Z, Huang X, Wang Z, Niu G, Hight Walker AR, Chen X. Glucose oxidase-catalyzed growth of gold nanoparticles enables quantitative detection of attomolar cancer biomarkers. *Anal Chem*. 2014;86(12):5800–6.
- Ngambenjwong C, Cieslewicz M, Schellinger JG, Pun SH. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. *J Control Release*. 2016;224:103–11.
- Puri A, Jang H, Yavlovich A, Masood MA, Veenstra TD, Luna C, Aranda-Espinoza H, Nussinov R, Blumenthal R. Material properties of matrix lipids determine the conformation and intermolecular reactivity of diacetylenic phosphatidylcholine in the lipid bilayer. *Langmuir*. 2011;27(24):15120–8.
- Rong P, Huang P, Liu Z, Lin J, Jin A, Ma Y, Niu G, Yu L, Zeng W, Wang W, Chen X. Protein-based photothermal theranostics for imaging-guided cancer therapy. *Nanoscale*. 2015;7(39):16330–6.
- Silver J, Li Z, Neuman K. Tethered-bead, immune sandwich assay. *Biosens Bioelectron*. 2015;63:117–23.
- Song J, Yang X, Jacobson O, Huang P, Sun X, Lisen L, Yan X, Niu G, Ma Q, Chen X. Biomedical applications: ultrasmall gold nanorod vesicles with enhanced tumor accumulation and fast excretion from the body for cancer therapy. *Adv Mat*. 2015;27(33):4805.
- Subramanian S, Aschenbach KH, Evangelista JP, Najjar MB, Song W, Gomez RD. Rapid, sensitive and label-free detection of Shiga-toxin producing *Escherichia coli* O157 using carbon nanotube biosensors. *Biosens Bioelectron*. 2012;32(1):69–75.
- Svarovsky SA, Barchi JJ Jr. Highly efficient preparation of tumor antigen-containing glycopeptide building blocks from novel pentenyl glycosides. *Carbohydr Res*. 2003;338(19):1925–35.
- Yavlovich A, Singh A, Blumenthal R, Puri A. A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubicin to cells. *Biochim Biophys Acta*. 2011;1808(1):117–26.
- Yavlovich A, Singh A, Tarasov S, Capala J, Blumenthal R, Puri A. Design of liposomes containing photopolymerizable phospholipids for triggered release of contents. *J Therm Anal Calorim*. 2009;98(1):97–104.

Submit your manuscript to a SpringerOpen<sup>®</sup> journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)